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Cellular locationSCFβTrCP is the ubiquitin ligase for a wide variety of substrates and functions inmany cellular processes. βTrCP,
the substrate binding factor of the SCF complex, has two isoforms, produced from different genes, and several
splice variants. Despite a certain level of redundancy, knock-out studies show different phenotypes indicating
different preferential substrates for the two isoforms. However, until now functional differences between
βTrCP1 and 2 were not studied at the endogenous protein level. We generated isoform-speciﬁc antibodies
against βTrCP to characterise endogenous βTrCP isoforms and splice variants. We show that endogenous
βTrCP1 and 2 localise to both nucleus and cytosol. Interestingly, we ﬁnd that one splice variant of βTrCP2
localises exclusively to the nucleus and another only to the cytosol. In addition, we show that the substrate
binding domain of βTrCP is the dominant localisation determinant.1, S-phase-kinase-associated-
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Protein ubiquitination affects the fate of target proteins in many
essential processes in the cell. The substrate speciﬁcity factors of the
ubiquitin proteasomal system, the ubiquitin ligases, bind to their
substrates and transfer ubiquitin directly or indirectly to their target
proteins [1]. The largest class of ubiquitin ligases are the Skp1-Cullin-
F-box protein (SCF) and SCF-like complexes. F-box proteins bind to
S-phase-kinase-associated-protein-1 (Skp1) via the N-terminal F-box
domain and to their substrates via a C-terminal binding domain [2].
β-transducing-repeat-containing protein (βTrCP) belongs to the
family of F-box proteins and was ﬁrst identiﬁed as an interaction
partner of the Human Immunodeﬁciency Virus-1 Vpu protein [3]. As
the F-box protein component of a SCF ubiquitin ligase complex, βTrCP
is involved in major regulatory mechanisms such as cell cycle
progression, metabolism, development, and immunity. Human cells
contain two βTrCP proteins, βTrCP1 encoded by BTRC, and βTrCP2
encoded by FBXW11, also known as HOS or βTRCP2 [1,4]. The E3
substrate binding domain of βTrCP is the WD40 domain repeat motif,
which contains seven WD40 repeats that are structured into a seven-
bladed propeller [1]. For Vpu, it has been shown that all repeats are
required for optimal substrate binding [5].
The cullin proteins (numbered 1–5, and 7) act asmolecular scaffolds
in the SCF complexes and bind with their N-terminus to Skp1 and withtheir C-terminus to RING-ﬁnger protein Rbx1 and to speciﬁc ubiquitin
conjugating enzymes (E2) [6]. In case of the interaction between the
SCF-complex and the E2 Cdc34, the rapid assembly and disassembly of
the E2–E3 complex facilitates ubiquitin chain synthesis. Moreover,
residues important for the dynamics of the complex are conserved,
suggesting that all SCF complexes and their E2's have the same
mechanism of chain assembly [7].
A large number of studies show that the structural requirements for
substrate recognition is not overly stringent, and conforms to a linear
motif of 6–9 amino acids starting with two acidic amino acid residues
followed by a small amino acid and another acidic moiety in the last
position. In β-catenin and IκB (inhibitor of NFκB), the second and last
positions constitute phosphorylated serine residues. Upstream of this
motif, one or several lysine residues serve as ubiquitin acceptors [8–10].
The F-box and WD40 domains of the two isoforms, βTrCP1 and
βTrCP2, are highly identical, 86 and 75%, respectively [11,12].Moreover,
their WD40 domains show very similar electrostatic surface properties,
with a conservation of the central groove covered by positively charged
amino acids that interact with the negatively charged residues in the
destruction motif of target proteins [13]. Indeed, many studies show
that the βTrCP isoforms are functionally redundant. This has been
reported for the degradation of Wee1, IκB, Per1 and the RE1-silencing
transcription factor (Rest) [14–17]. Conversely, speciﬁcity exists for the
early mitotic inhibitor 1 (Emi1) that explicitly requires βTrCP1 for its
degradation [18,19]. In addition, genetic evidence from gene knock-out
experiments in mice shows that βTrCP2 is essential in early develop-
ment while deletion of βTrCP1 does not affect viability but impairs
spermatogenesis and reduces fertility [18]. This implies that, although
both isoforms occur in all or most cells, they have marked features that
cause these differences. The phenotypes may arise from differences in
local concentrations, substrate binding, turnover, or expression.
However, all these parameters are inferred from structural differences
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isoforms and their splice variants. In humans, two splice variants of
βTrCP1, α and β (without the second exon), and three of βTrCP2, α, β,
(with an alternative second exon) and γ (without the second exon), are
predicted to exist.
In this study, we show for the ﬁrst time the localisation of
endogenous βTrCP1 and 2 isoforms and splice variants using isoform-
speciﬁc antibodies. We ﬁnd that βTrCP1 and 2 are both present in the
nucleus as well as in the cytosol, whereas a striking difference in
localisation between two splice variants of βTrCP2was observed:while
βTrCP2γ resides exclusively in the cytosol, βTrCP2β is solely detectable
in the nucleus.
2. Materials and methods
2.1. Cell culture and transfections
HEK293 cells were cultured in 4.5 g/l glucose (Invitrogen), supple-
mented with 10% fetal bovine serum (Invitrogen), 100 units/ml
penicillin, 0.1 mg/ml streptomycin (both Invitrogen). HEK293 cells,
stably expressing the Tet-repressor (HEKTR), were a gift of Dr. Madelon
Maurice and were maintained in DMEM with 4.5 g/l glucose, supple-
mentedwith 10% fetal bovine serum, 100 units/ml penicillin, 0.1 mg/ml
streptomycin and 12 μg/ml Blasticidin-S (MP Biomedicals). HEKTR cells,
stably expressing βTrCP1 or 2 (upon 1 ng/ml doxycyclin addition)
(HEKTR_iTrCP), were cultured in the maintenance medium for HEKTR
cells, supplemented with 170 μg/ml zeocin (Invitrogen). HEKTR_iTrCP
cells that were either stably transfectedwith GHR (HEKTR_GHR_iTrCP1
or 2), were cultured in HEKTR_iTrCP maintenance medium, supple-
mented with 600 μg/ml geneticin (Invitrogen).
2.2. Transfections, DNA constructs and siRNA
Wild type GHR in pcDNA3.1, GFP siRNA and βTrCP siRNA were
described before, as were wild type Flag-βTrCP2, Flag-βTrCP2(ΔWD40),
βTrCP2(WD40), βTrCP2(ΔF) and βTrCP2(ΔD) [20]. Inducible βTrCP1β
and 2αwere constructed by cloningβTrCP1β andβTrCP2α into pcDNA4/
TO (Invitrogen), Tet-repressor is in pcDNA6andGST-βTrCP1β (1–93) and
GST-βTrCP2α (1–68) are in pGEX1λt. βTrCP1α (1–167) (from clone
IRAKp961E0762Q2 obtained from RZPD) and β (1–131) were expressed
in a pcDNA4/TO vector. EST clones containing N-terminal fragments of
TRCP2β and γ were a gift from Dr. Gabor Gyapay (Genoscope). DNA
transfections were performed using FuGene6 (Roche) and siRNA
transfections with lipofectamine 2000 (Invitrogen) according to the
manufacturer's instructions.
2.3. Antibodies and materials
Anti-GHR(B) was described before [21]. Anti-Flag polyclonal and
anti-Myc monoclonal were from Sigma. Leptomycin B, used for 12 h at
10 ng/ml, was purchased from Sigma. Cycloheximide was bought from
ICN andwas used at 100 μg/ml. Doxycyclinwas obtained fromClontech.
Biotin-GH was described before [22].
2.4. Antibody generation and afﬁnity puriﬁcation
GST fusion proteins of residues 1–93 of βTrCP1β and residues 1–68
of βTrCP2α were injected into rabbits and antisera were obtained. We
afﬁnity puriﬁed the antisera using CNBr activated Sepharose-4 beads
(Pharmacia), according to the manufacturer's manual.
2.5. Preparation of nuclear, cytosolic and membrane fractions
Subconﬂuent cells were collected with trypsin-EDTA (Invitrogen)
andwashedwith phosphate-buffered saline (PBS), after which the cells
were washed two times in hypotonic buffer (10 mM HEPES pH 7.9,1.5 mM MgCl2, 10 mM KCl, 1 mM dithiothreitol (DTT), 0.5 mM
phenylmethylsulphonyl ﬂuoride (PMSF), 10 μg/ml leupeptin and
10 μg/ml aprotinine), after which the cells were incubated in hypotonic
buffer on ice for 10 min. The cells were dounced 50 times with a B-type
pestle, after which the lysates were centrifuged for 5 s at 16,000×g. The
supernatant was fractionated into a cytoplasmic and a membrane
fraction by centrifugation at 100,000×g for 1 h. The pelletwaswashed 2
times with hypotonic buffer and designated as the nuclear fraction.
2.6. Immunoﬂuorescence and confocal microscopy
HEKTR_GHR_iTrCP1 or 2 cells were grown on cover slips. The cells
were washed and ﬁxed with 3% paraformaldehyde in 0.1 M sodium-
phosphate buffer pH 7.4. After washing with PBS, the cells were
incubated with 0.02 M NH4Cl for 5 minutes. Subsequently, cells were
incubated with 0.2% TritonX-100 for 5 min, followed by three washes
with PBS. 0.5% bovine serum albumin (BSA) was added for 15 min and
the primary antibody in 0.5% BSA was left on the cells for 30 min. The
cells were washed with 0.5% BSA and incubated with Alexa goat
anti-rabbit 488 (Molecular probes) for 30 min. After washing with
0.5 mg/ml BSA in PBS and PBS, the cellsweremountedwithmowiol and
analysed using a confocal microscope.
2.7. Cell lysis, immunoprecipitation and biotin-GH pull down
Cell lysates were prepared by washing the cells with cold PBS, after
which the cells were lysed with 1% Triton X-100, 1 mM EDTA, 10 μg/ml
aprotinin, 10 μg/ml leupeptin and 1 mMPMSF in PBS for 15 min. For the
turnover experiments, the cell lysates were prepared by incubating the
cells in a buffer containing 1% sodium dodecyl sulphate (SDS), 1 mM
EDTA, 10 μg/ml aprotinin, 10 μg/ml leupeptin and 1 mMPMSF in PBS for
10 min at 100 °C. The lysates were centrifuged for 5 min and the
supernatants were used for immunoprecipitations by incubation with
anti-myc for 2 h followed by incubation of 45 min with protein A
agarose beads. Biotin-GH pull down was performed by incubating the
lysates for 1 h with biotin-GH, followed by a 30-min incubation with
streptavidin agarose beads. Lysates, immunoprecipitates and pull down
samples were subjected to SDS-PAGE and western blotting, after which
the membranes were detected with the indicated antibodies. Western
blots were analysed using an Odyssey infrared imaging system and
quantiﬁed using Odyssey software (Li-Cor Biosciences, Lincoln, NE).
2.8. Tissue proﬁling and RT-PCR
TissueproﬁlingwasdoneusingClontechHumanMultipleTissuecDNA
panels I and II and PCR was done according to the user's manual. The
following primers were used: βTrCP1 forward primer GATCGGATCCATG-
GACCCGGCCGAGGCG, βTrCP1 reverse primer: GTACGCGGCCGCGTGCC-
CATGTTGGTAATGAC, βTrCP2 forward primer TTTGGATCCATGG-
AGCCCGACTCGGTGATTGAGGAC and βTrCP2 reverse primer
GTACGCGGCCGCATGACCATGCTGATAATGAC. The same primers were
used to perform a RT-PCR for βTrCP1 and 2 on the RNA isolated from
HEK293 cells. DNA products were veriﬁed by direct sequencing.
3. Results
3.1. Detection of βTrCP1 and 2 isoforms by speciﬁc antibodies
In order to identify differences between endogenousβTrCP isoforms
and splice variants that might account for their functional differences,
we generated isoform-speciﬁc antibodies. The schematic structure of
βTrCP, depicted in Fig. 1A, shows a variable domain in the N-terminus.
Therefore, we selected the variable domains of βTrCP to generate
antibodies speciﬁc for either βTrCP1 or 2. The splice variants are
identiﬁable by their differences in molecular weight. To test antibody
sensitivity and speciﬁcity, we prepared nuclear and cytosolic fractions
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shows expected bands of ~60 kD and 50 kD for endogenousβTrCP1 and
2, respectively, indicating that the antibodies are capable of detecting
endogenous βTrCP. To determine whether the observed bands are
speciﬁc, we depleted the cells for βTrCP with a siRNA probe directed
against both βTrCP1 and 2 and a control siRNA (GFP). As shown in
Fig. 1B, the bands detected inGFP-silenced cells completely disappeared
in βTrCP-silenced cells. Importantly, the band detected by anti-βTrCP1
was not detected by anti-βTrCP2 and vice versa, which shows that the
antibodies are isoform-speciﬁc. With the βTrCP2 antiserum, we
detected one abundant background band that was present only in the
nuclear fraction,whichwasnot silencedwithβTrCP siRNA. These results
clearly indicate that the antibodies are speciﬁc and can be used to
identify differences in cellular localisation, substrate binding and
turnover.
3.2. Endogenous and exogenous βTrCP1 and 2 localise to both nucleus and
cytosol
Oneobviousexplanation for substrate-speciﬁcityofβTrCP1and2 is a
different localisation. To localise the isoforms in the cell, we used
HEKTR-cells that express eitherβTrCP1or 2 fromadoxycyclin-inducible
DNA construct. After treatment with doxycyclin, we stained with
afﬁnity-puriﬁed βTrCP1 and 2 antibodies and visualised the cells using
confocal microscopy. Fig. 2A shows that induction of exogenous βTrCP1
and 2 resulted in a strong increase in signal intensity, indicating that the
antibodieswork after formaldehydeﬁxationof cells. The vehicle-treated
cells show that endogenous βTrCP1 and 2 both localise to both the
cytoplasm and the nucleus. The same localisations were detected for
exogenous (doxycyclin-induced) βTrCP. Leptomycin B treatment,
which results in inhibition of nuclear export via XPO1/CRM1, resulted
in localisation of both (endogenous) isoforms in the nucleus (Fig. 2B),
indicating that they shuttle between the nucleus and the cytosol.
Together, these results show no differences for the localisation of
βTrCP1 and 2 isoforms. Both endogenous and exogenous βTrCP
isoforms are present in the nucleus and the cytoplasm. The effect ofFig. 1. Characterisation of antibodies against the N-termini of βTrCP1 and 2. (A) Schematic re
variants. V=Variable domain, D=Dimerisation domain, F=F-box. The variable domain
production in rabbits. (B) HEKTR cells were silenced as indicated for GFP and βTrCP followed
the indicated antibodies. The asterisk indicates a background band.leptomycin also illustrates that the speciﬁcity of the antibodies as the
treatment reduces labelling of the cytosol to background values.3.3. βTrCP splice variants localise differently within the cell
In a previous studywithmouse cells, 8 splice variants for bothmouse
βTrCP1 and 2 were identiﬁed. To determine the occurrence of βTrCP
splice variantmRNAs in humanHEKTR-cells, we performed RT-PCR and
detected two abundant human splice variants for βTrCP1 (α and β) and
two for βTrCP2 (β and γ) (Fig. 3A). For βTrCP1, one extra low abundant
splice variant was detected, which we named βTrCP1α'. Surprisingly,
βTrCP2α RNA, used inmost overexpression studies, was not detected in
HEKTR cells.
As immunoﬂuorescence was unable to distinguish the different
βTrCP splice variants, we performed cell fractionation. In nuclear and
cytosolic fractions of doxycycline-inducible HEKTR_iTrCP1 or 2 cells we
detected only one endogenous splice variant ofβTrCP1, whichmigrated
as exogenous βTrCP1β (Fig. 3B). As the mRNA of both βTrCP1α and β
splice variants are produced in HEK293 cells (Fig. 3A) and the βTrCP1
antibody recognises both βTrCP1α and β variants (Fig. 3D), it might be
that the difference in molecular weight is too small to distinguish
βTrCP1α fromβ onwesternblot. Another explanationwould be that the
protein βTrCP1α is unstable. We conclude from our immunoﬂuores-
cence data that endogenous βTrCP1 and exogenous βTrCP1β localise to
both the cytoplasm and the nucleus.
We detected two endogenous βTrCP2 isoforms, of which the fast-
migrating one was present in the cytosol and the slow-migrating one
was found in the nucleus. Since the exogenous βTrCP2 is the α-variant,
the endogenous faster-migrating TrCP2 splice variants are very likely
the β and γ variants. The absence of endogenous βTrCP2α is supported
by the RT-PCR data (Fig. 3A). This is in agreementwith a previous study
in mouse tissues, in which it was shown that the most commonly used
βTrCP2α splice variant is expressed to a very low extent [23]. Together,
the results present evidence that the βTrCP2 antibodies recognise both
the β and γ splice-variants as they contain exactly the same amino acidpresentation of the structural organisation of the isoforms βTrCP1 and 2 and their splice
s of βTrCP1β and 2α were expressed as GST fusion proteins and used for antibody
by the preparation of cytosolic and nuclear fractions. Western blot were detected with
Fig. 2. Both endogenous and exogenous βTrCP1 and -2 localise to both the nucleus and the
cytosol. (A) HEKTR_iTrCP1 or 2 cells were treatedwith vehicle or doxycyclin, afterwhich the
cells were immunolabelledwith afﬁnity-puriﬁed anti-βTrCP1 or 2 and visualised by confocal
microscopy. (B)HEKTR_iTrCP1 or 2 cells were treated overnight with vehicle or 10 ng/ml
leptomycin B, after which the cells were labelled with afﬁnity-puriﬁed anti-βTrCP1 or 2 and
visualised by confocal microscopy. Microscopy settings were the same for all pictures.
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rabbits.
Since several cell surface signalling receptors are βTrCP substrates,
we investigated whether βTrCP that is outside the nucleus, is
membrane-bound or cytosolic. As shown in Fig. 3C and already
indicated by the granular appearance in Fig. 2B, endogenous βTrCP1
and 2 aremainly attached tomembranes rather than existing free in the
cytosol. In contrast, membrane-bound and cytosolic exogenous βTrCP1
and 2 levels are similar, probably because the substrates at the plasma
membranes are saturated with βTrCP due to high expression levels of
βTrCP.
Immunocytochemical data suggest that βTrCP1 is mainly responsible
for ubiquitination of nuclear substrates, including ATF4 and Emi1 [19,24],
while βTrCP2 is also involved in cell surface receptor degradation [20,25].
SinceβTrCP2α localises to both nucleus and cytosol, we chose this variant
to deﬁne a localisation motif or domain and constructed several
Flag-tagged βTrCP mutants: lacking either the F-box (ΔF), the
dimerization domain (ΔD) or the WD40 domain (ΔWD40) or only the
WD40 domain (WD40). Fig. 3E clearly shows that wild type βTrCP2α ishighly abundant in the nucleus compared to the cytosol. In contrast,
the ΔWD40 mutant shows an equal distribution between nucleus and
cytosol, demonstrating that the WD40 domain is important for nuclear
localisation. Aswild typeβTrCP, theWD40 domain itself localised to the
nucleus. In fact, all mutant βTrCP species with an intact WD40 domain
distributed equally, supporting the notion that the localisation of βTrCP
is dictated by the location of its substrates.
3.4. Both βTrCP1 and 2 are stable proteins
As it has become clear that ubiquitin ligases can auto-ubiquitinate,
the stability of ubiquitin ligases is an important parameter in major
regulatory processes.βTrCP2 is stabilised in the presence of phosphory-
lated substrates [26]. To determine the stability of endogenous βTrCP1
and 2, we treated HEKTR cells with cycloheximide and quantiﬁed
endogenous βTrCP1 and 2 levels after different chase periods. Fig. 4
clearly shows that the turnover of both βTrCP1 and 2 is low, since after
four and a half hours not even half of the proteins were degraded. We
conclude that the half lives of endogenous βTrCP1 and 2 isoforms are
similar, demonstrating that the turnover does not contribute to their
differential cellular function.
3.5. Tissue distribution of RNA levels of splice variants of βTrCP1 and 2
Based on the ﬁnding that splice variants localise differently in cells,
we speculated that different cell types use differential alternative
splicing to regulate the level of speciﬁc variants of βTrCP in cells.
Therefore, we performed a RT-PCR on a variety of tissues and
determined whether their mRNA levels varied among these tissues.
Fig. 5A shows that three mRNAs of βTrCP1 were detectable instead of
the predicted two, just like we observed in Fig. 3A. These data are in
agreement with a study from Seo et al. [23]. Out of the three detected
mRNAs, two are very abundant in several tissues (α andβ),whereas the
α' variant is predominantly expressed in testis. βTrCP1 mRNA levels
vary considerably in different tissues (Fig. 5A), so it might be that
different cell types do not equally depend on the various splice variants.
For βTrCP2, we detected four mRNA splice variants; β, γ and two splice
variants indicated with asterisks (Fig. 5B). The mRNAs of these two
splicevariantswere alsodetected by Seo et al. [23], butwedid not detect
either of them at the protein level, suggesting that the proteins are
unstable. Although the signalswere low forβTrCP2β andγ (Fig. 5B), the
RNA expression patterns of the tested tissues seem to differ, suggesting
that regulation ofβTrCP2mRNA splicingmight be amechanism for cells
to regulate βTrCP2 splice variant levels.
4. Discussion
The importance of SCFβTrCP is reﬂected by its involvement in key
processes in the cell, such as the NFκB and theWnt signalling pathways.
Many studies have been performed in order to identify which βTrCP
isoform acts on a given substrate. Because of the lack of antibodies
recognizing endogenous βTrCP, these studies were all done with
exogenous βTrCP, in particular βTrCP1β and 2α. Overexpression of a
protein might result in aberrant localisation, substrate binding
characteristics or half life compared to the endogenous protein. As a
consequence of using exogenous βTrCP, most studies investigated only
one particular splice variant. Our isoform-speciﬁc antibodies enabled a
precise study of localisation, substrate afﬁnity and turnover of
endogenous βTrCPs.
We found that both endogenousβTrCP1 and 2 isoforms are localised
in the nucleus as well as in the cytosol. However, whereas endogenous
βTrCP2β was exclusively found in the nucleus, endogenous βTrCP2γ
was found only in the cytosol. Moreover, we showed that the substrate
bindingdomain is an important factor for nuclear localisation. However,
in case of the different location of βTrCP2β and 2γ this cannot be
contributed to their (identical) WD40 domain. The variable N-termini
Fig. 3. Expression pattern and cellular localisation of βTrCP2 splice variants. (A) RNA was isolated from HEK293 cells and a RT-PCR with primers speciﬁc for either βTrCP1 or 2 was
performed.DNA fromknownsplicevariantswas usedaspositive control. (B)HEKTR_iTrCP1 andHEKTR_iTrCP2cellswere treatedwith andwithoutdoxycyclin followedby thepreparation
of cytosolic (C) and nuclear (N) fractions. The fractions were analysed on western blot using afﬁnity-puriﬁed anti-βTrCP1 or 2. On the right, the splice variants are indicated.
(C) HEKTR_iTrCP1 and HEKTR_iTrCP2 cells were treated with doxycyclin followed by the preparation of nuclear (N) and crude cytosolic (CC) fractions. The CC fractions were further
separated into cytosolic (C) andmembrane (M) fractions. The fractionswere analysed as in Fig. 3B. On the right, the splice variants are indicated. The data are shown as typical examples of
three independently performed experiments. (D)βTrCP1α 1–167 andβTrCP1β 1–131were expressed inHEKTR cells and detectedwith anti-βTrCP1. (E) Flag-taggedβTrCPmutantswere
expressed in HEKTR cells followed by the preparation of cytosolic and nuclear fractions. The fractions were analysed on western blot using anti-Flag followed by quantiﬁcation using
Odyssey software. Data are displayed as mean values of three experiments±SD.
645J. Putters et al. / Cellular Signalling 23 (2011) 641–647might play a role as well. Both endogenous βTrCP1 and 2 isoforms that
are located outside the nucleus are mainly membrane-localised. As the
substrate binding domain appears the dominant localisation factor, it is
tempting to speculate that most of the processes outside the nucleus
that involve βTrCP occur membrane-associated. In contrast, exogenousβTrCP is distributed equally over cytosol and membrane fractions,
indicating that high βTrCP expression levels saturate the βTrCP
substrates located at the membrane with βTrCP. Excess βTrCP that
does not encounter a substrate on themembrane will mislocalise in the
cytosol.
%
 βT
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Cycloheximide (h)
βTrCP1
βTrCP2
100
75
50
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Fig. 4. Endogenous βTrCP1 and 2 have relatively long half lives. HEKTR cells were treated
with cycloheximide and lysed after the indicated time points. βTrCP1 and 2 levels were
analysed on western blot and quantiﬁed using Odyssey software. Data are means of four
independent experiments±SD.
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splicevariants suggest that their regulation is important, especially since
βTrCP binds concentration-dependently to some substrates instead of
recognising the phosphorylated DSGXXS motif. This principle of
concentration-dependent βTrCP binding implies that uncontrolled
βTrCP expression might result in the development of tumours, because
manyβTrCP substrates are key players in the regulation ofmany cellular
processes that are related to cell division and cancer [27]. In GHR, βTrCP
binds to the endocytosis motif (DDSWVEFIELDIDD) without any
modiﬁcations and its ligase activity probably depends mainly on theFig. 5. Tissue proﬁling of βTrCP1 (A) and βTrCP2 (B) mRNA levels. Asterisks indictated in (
detected on the protein level. Data are representative of two independent experiments.cytosolic concentration of the βTrCP2γ variant. GH stimulation of the
GHR results in an elevated Insulin-like Growth Factor-I (IGF-I) level,
which has been associatedwith a number of cancers. IGF-I levels can be
reduced by blocking GH-binding to GHR or by upregulation of βTrCP2γ
[28]. The tumour suppressor TAp63γ also seems to bind βTrCP without
upstream action of a kinase. In contrast tomany other substrates, βTrCP
binding stabilises TAp63γ, resulting in G1 cell cycle arrest [29]. In such
conditions, uncontrolled βTrCP expression could result in improper
regulation of the cell cycle and cancer.
Despite thehigh substrate diversity, it has been suggested thatβTrCP
is tumour-promoting and is considered anoncogene. This is reﬂected by
an increased expression of βTrCP in a variety of cancers, whereas
mutations in βTrCP are rarely found in human tumours and primary
cancers. Striking examples are hepatocellular carcinomas, which show
constitutive NFκB activation together with high βTrCP levels [29–31]. In
addition, some cancers are speciﬁcally associatedwith one of the βTrCP
isoforms, like βTrCP1 in hepatoblastomas and colorectoral cancers and
βTrCP2 in breast/gastric and prostate cancers. Fig. 5 shows that different
cell types have differences in βTrCP splice variant mRNAs, suggesting
that also differential expression of βTrCP splice variants might be
relevant for the development of cancers. Not only expression of the
functional, but also of the non-functional βTrCP splice variants is
important for a given substrate. βTrCP variants that bind to, but are not
functional towards a given substrate might act as dominant-negative.
Another way of regulating βTrCP isoform levels might be binding of the
WD40 domain of βTrCP1 and not 2 to pseudosubstrate hnRNP-U [32].
Possibly, more proteins with a similar function are expressed in cells. In
addition, proteins can regulateβTrCPexpression in cells,whichhas been
shown for BRAF in human melanoma cells [29].
βTrCP acts within the SCF complex and requires the other SCF
components for its activity. The high levels of βTrCP observed in
tumours suggest that βTrCP is the limiting factor for activity of the SCFB) show two βTrCP2 splice variants in addition to the β and γ variants that were not
647J. Putters et al. / Cellular Signalling 23 (2011) 641–647complex. This idea is supported by the fact that βTrCP overexpression in
cells often results in accelerated degradation of its substrates, indicating
that the other SCF components are not limiting.
Together, we conclude that localisation is different between βTrCP
variants, suggesting that this parameter is important for their function.
The presented ﬁndings on βTrCP are important to understand the
mechanism of action of βTrCP and its role in cancer.
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